Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

Omeros third quarter net loss increases to $7.6 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

4 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

OPKO acquires major share in Fabrus

OPKO Health, Inc. announced that it has made an investment in Fabrus, LLC, a privately held early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities. In exchange for the Company's investment, the Company acquired approximately 13% of Fabrus' outstanding membership interests on a fully diluted basis.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

PharmAthene closes public offering of common stock

PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has closed its previously announced registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

APS summit focuses on Antiphospholipid Syndrome research

Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages. Nonetheless, relatively few randomized clinical trials have been conducted involving people with APS, and those completed have included small numbers of participants.

3 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010